What questions should I ask my doctor at my next appointment

Questions to Ask Your Doctor at Your Next Appointment

Based on reviewing Marlo's [ID removed] here are targeted questions organized by topic that will help you engage in shared decision-making with your care team:

ABOUT THE DIAGNOSIS & TUMOR BIOLOGY

1. Clarifying the diagnosis: The pathology reports describe a "low-grade spindle cell neoplasm of myofibroblastic origin" with cartilaginous metaplasia. Can you explain what this means for Marlo's prognosis and treatment options compared to other spindle cell sarcomas?

2. EGFR mutations: I see testing identified EGFR ITD (internal tandem duplication) and KDD (kinase domain duplication) mutations. How common are these in spindle cell sarcomas, and what do they tell us about which treatments might work best?

3. Tumor microenvironment: The records mention a "cold" immune environment. What does this mean, and how does it affect treatment decisions?

ABOUT MOLECULAR TESTING & NEXT STEPS

1. Biopsy timing: Should we do another biopsy before starting new treatment, or after? Which tumor site would give the best information?

2. Comprehensive profiling: The treatment strategy document mentions several testing options (organoid development, PDX models, whole genome sequencing, immunopeptidomics). Which of these would be most helpful for Marlo's specific situation, and which are covered by insurance?

3. Tissue coordination: Can all the different labs (TRACER, Certis, BostonGene, CD Genomics) use tissue from a single biopsy, or do we need multiple samples?

4. Turnaround times: How long will results take from each testing platform, and when should we expect recommendations?

ABOUT SYSTEMIC THERAPY OPTIONS

1. Current therapy assessment: How is Marlo responding to current treatment? What markers are you using to measure response?

2. Afatinib switch: The strategy document mentions afatinib (an irreversible pan-HER inhibitor) as a potential option. What evidence would support switching from current therapy, and what are the side effects we should watch for?

3. MET inhibitor combination: Should we consider adding a MET inhibitor alongside EGFR-targeted therapy? Does Marlo's tumor show MET amplification or overexpression?

4. Drug interactions: Are there any interactions between potential new therapies and Marlo's current medications?

ABOUT RADIATION THERAPY

1. Radiation strategy: Is radiation therapy recommended for Marlo's tumor location and biology? If so, when—before or after systemic therapy?

2. Carbon ion therapy: Is carbon ion radiation therapy (CIRT) appropriate or accessible for this tumor type? Are there centers you'd recommend?

3. Ablative approaches: Could radioablation or cryoablation play a role in managing this tumor?

ABOUT IMMUNOTHERAPY & CLINICAL TRIALS

1. Peptide vaccine development: Is neoantigen-based vaccine development something we should pursue? Which labs do you recommend for immunopeptidomics analysis?

2. CAR-T eligibility: St. Jude has a B7-H3 CAR-T trial (3CAR). Is Marlo eligible, and would this be appropriate given the "cold" tumor environment? Should we consider immune-priming strategies first?

3. FAP-targeted therapy: I've read about FAP (fibroblast activation protein) radioligand therapy being used in pediatric sarcomas in Germany. Does Marlo's tumor express FAP, and is this an option we should explore?

4. Clinical trial search: Are there any open trials specifically for EGFR-altered sarcomas, ADC (antibody-drug conjugate) trials, or other novel approaches Marlo might be eligible for?

ABOUT SEQUENCING & TIMING

1. Treatment sequence: What's the optimal order for these interventions? Which decisions are time-sensitive versus ones we can wait on for more data?

2. Synergies between approaches: Could combining approaches (like vaccine + CAR-T, or immunotherapy + targeted therapy) be more effective than single approaches?

ABOUT PATHOLOGY REVIEW

1. Expert consultation: The Mayo Clinic report mentions seeking external pathology consultation. Has Cleveland Clinic or another sarcoma pathology expert reviewed Marlo's case? What did they recommend?

2. Diagnosis confidence: Given that the diagnosis has been described as "elusive," how confident are you in the current diagnosis, and could additional testing clarify it further?

ABOUT MONITORING & SIDE EFFECTS

1. Monitoring plan: How often will Marlo need imaging and lab work? What are we looking for to assess treatment response?

2. Side effect management: What side effects should we watch for with any new treatments, and when should we contact you?

3. Quality of life: How can we balance aggressive treatment with maintaining Marlo's quality of life and normal activities?

---

HOW TO USE THESE QUESTIONS

• Prioritize: You won't ask all 25 at once. Pick the 5-7 most important to you for this appointment.
• Bring notes: Write down the questions and take notes on the answers.
• Bring records: Consider bringing copies of the key test results to reference during discussion.
• Follow-up: If you don't understand an answer, ask for clarification or request written summaries.
• Document: Ask if the doctor can document their recommendations in writing for your records.

---

RESOURCES TO REVIEW BEFORE YOUR APPOINTMENT

According to NCCN Guidelines for Soft Tissue Sarcoma and American Cancer Society recommendations, understanding your tumor's specific molecular features (like the EGFR mutations) is increasingly important for treatment planning. The National Cancer Institute (NCI) also has information about clinical trials that may be relevant.

The strategy document your team has created shows thoughtful, comprehensive planning. Using these questions will help ensure you and your doctors are aligned on priorities and next steps.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.